Citigroup reiterates Sepracor at buy

Sepracor Inc. was reiterated by Citigroup Investment Research analyst Andrew Swanson at buy after the company reported first-quarter earnings of $0.09 per share, falling short of the analyst's $0.28 forecast and the $0.29 consensus forecast. Revenue was in line with Citigroup's estimate at $286 million, and heavily dependent on the Xopenex franchise than on Lunesta. Shares of the Marlborough, Mass., pharmaceutical company were down $1.40, or 3.15%, at $43.03 on volume of 7,882,751 shares versus the three-month running average of 2,452,980 shares. (Nasdaq: SEPR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.